drugset / Trial / NCT06033820
Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single center, single arm, open label study of zanubrutinib, lenalidomide in combination with Rituximab-ICE for treatment of relapsed/refractory diffuse large B-cell lymphoma.
Timeline
- Start
- 2023-10-12
- Primary completion
- 2025-06-30
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | — | Oral |
| Subject | Zanubrutinib | Small molecule | — | Oral |